Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, novembre 17
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Filana Therapeutics Inc
FLNA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.4700
Dern. MÀJ: Nov 17, 8:53 AM
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Filana Therapeutics Financials
Filana Therapeutics (FLNA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Filana Therapeutics Sees H2 2026 Net Cash Used In Operations Of $11M-$15M; Year-End Cash $38M-$42M
Benzinga Newsdesk
PRO
Filana Therapeutics Expects Patient Screening In Phase 2a Study Of Simufilam In TSC-Related Epilepsy To Begin By Q1 2027, Following FDA Lift Of Clinical Hold In September
Benzinga Newsdesk
PRO
Filana Therapeutics Q3 GAAP EPS $(0.22) vs $(0.22) YoY
Benzinga Newsdesk
PRO
Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of $(0.92) per share
Benzinga Newsdesk
PRO
Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
Benzinga Newsdesk